Skip to content
type1.science

VX-017 blood-type-independent stem-cell islets

Vertex Pharmaceuticals

IND cleared, not yet human evidence.

Vertex's newly named stem-cell-derived, fully differentiated islet-cell therapy, designed for eligible people with type 1 diabetes regardless of blood type. The FDA has cleared its IND and Vertex plans a Phase 1/2 study in the near term, but no trial record or human results existed by 8 August 2026.

Not availablePreclinicalstem-cellisletcell-therapyind-clearedblood-type-independent

The scorecard

Insulin independence5

VX-017 is intended to replace islet function, but Vertex has disclosed no human efficacy data and has not said that recipients became insulin-free.[1]

Durability5

No human has been reported treated, so graft survival and durable glucose control are unknown.[1]

Immunosuppression-free5

Vertex has not publicly stated whether VX-017 requires systemic immunosuppression; blood-type independence must not be read as immune evasion or immunosuppression independence.[1]

Eligibility breadth15

Vertex says the product is designed for eligible people with T1D regardless of blood type, but the actual Phase 1/2 eligibility criteria have not been disclosed.[1]

Maturity20

The IND is cleared, but the planned Phase 1/2 study had not appeared on ClinicalTrials.gov and no participant had been publicly reported dosed by 8 August 2026.[2]

The full picture

Vertex disclosed VX-017 on 3 August 2026 as a stem-cell-derived, fully differentiated islet-cell therapy whose FDA investigational new drug application had been cleared.1 The company says it is designed to treat eligible people with type 1 diabetes regardless of blood type and that a Phase 1/2 study will begin in the near term.1

That is the full evidence boundary. Vertex has not disclosed VX-017's delivery route, trial eligibility, immune-engineering strategy or immunosuppression regimen. In particular, “regardless of blood type” does not mean “immunosuppression-free.” No ClinicalTrials.gov record matched VX-017 when checked on 8 August 2026, and there are no reported participant outcomes.2

The next useful evidence is therefore not an approval forecast. It is the first protocol: who can enroll, how the cells are delivered, what immune management is required, and whether the first recipients show safe engraftment and glucose-responsive C-peptide. Vertex expects to provide updated timelines for both VX-017 and zimislecel later in 2026.1

References

  1. Vertex Pharmaceuticals. Vertex Reports Second Quarter 2026 Financial Results. 3 August 2026. https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm ↩ ↩2 ↩3

  2. ClinicalTrials.gov search for “VX-017”, checked 8 August 2026. https://clinicaltrials.gov/search?term=VX-017 ↩

Coming soon

ETA · FDA IND cleared; Phase 1/2 planned in the near term, with updated program timelines expected later in 2026. No approval ETA is supportable.

  • →First Phase 1/2 protocol, eligibility details and dosing · Planned in the near term; no registered trial as of 8 August 2026
  • →Vertex update on the VX-017 development timeline · Expected later in 2026

Sources

  1. [1]Vertex reports second-quarter 2026 financial results · manufacturer · 2026-08-03 — Primary company release filed with the SEC. It says the FDA cleared the IND and a Phase 1/2 study is planned in the near term, but gives no route, immune-engineering description, immunosuppression regimen, or human data.
  2. [2]ClinicalTrials.gov search for VX-017 · registry — No matching study record was present when checked on 8 August 2026.